Correction of a pathogenic gene mutation in human embryos
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Genome editing has potential for the targeted correction of germline mutations. Here we describe the correction of the heterozygous MYBPC3 mutation in human preimplantation embryos with precise CRISPR-Cas9-based targeting accuracy and high homology-directed repair efficiency by activating an endogenous, germline-specific DNA repair response. Induced double-strand breaks (DSBs) at the mutant paternal allele were predominantly repaired using the homologous wild-type maternal gene instead of a synthetic DNA template. By modulating the cell cycle stage at which the DSB was induced, we were able to avoid mosaicism in cleaving embryos and achieve a high yield of homozygous embryos carrying the wild-type MYBPC3 gene without evidence of off-target mutations. The efficiency, accuracy and safety of the approach presented suggest that it has potential to be used for the correction of heritable mutations in human embryos by complementing preimplantation genetic diagnosis. However, much remains to be considered before clinical applications, including the reproducibility of the technique with other heterozygous mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Germline editing has been used for years in animals, including mice, rats, monkeys and many others, and experiments show that it can be done in both nonviable or viable human embryos as well 110-113 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [112]
In the citing paper
“Of the studies that have been conducted, the reported efficiencies of repair with templates in human embryos are very low (5,7,8).”
From Frequent loss of heterozygosity in CRISPR-Cas9–edited early human embryos (2021) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Orthwein, A. et al. Mitosis inhibits DNA double-strand break repair to guard against telomere fusions. Science 344, 189–193 (2014)”
Cited work 10.1126/science.1248024 · retracted 2025-01-09 · notice 10.1126/science.adv1263 · this paper published 2017-08
Citations
Cites
1 retracted
Mitosis Inhibits DNA Double-Strand Break Repair to Guard Against Telomere Fusions
Orthwein, A., Fradet-Turcotte, A., Noordermeer, S. M., Canny, M. D., Brun, C. M., Strecker, J., Escribano-Diaz, C., & Durocher, D. (2014) · Science · doi:10.1126/science.1248024 · Cited by 319
RetractedA Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationAntoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Cited by
Items 301–400 of 948
Embryo and fetal gene editing: Technical challenges and progress toward clinical applications
Mattar, C. N. Z., Chew, W. L., & Lai, P. S. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101229 · Cited by 26
CRISPR fixes disease gene in viable human embryos
Ledford, H. K. (2017) · Nature · doi:10.1038/nature.2017.22382 · Cited by 41
Is Precision Medicine the Future of Healthcare?
Barker, R. (2017) · Personalized Medicine · doi:10.2217/pme-2017-0060 · Cited by 26
Modelling genetic diseases for drug development: Hypertrophic cardiomyopathy
Santini, L., Palandri, C., Nediani, C., Cerbai, E., & Coppini, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105176 · Cited by 24
Ethics and Genomic Editing Using the Crispr-Cas9 Technique: Challenges and Conflicts
Lorenzo, D., Esquerda, M., Palau, F., Lasaosa, F. J. C., & de Bioètica, G. I. (2022) · NanoEthics · doi:10.1007/s11569-022-00425-y · Cited by 31
Harnessing CRISPR/Cas9 technology in cardiovascular disease
Rezaei, H., Khadempar, S., Farahani, N., Hosseingholi, E. Z., Hayat, S. M. G., Sathyapalan, T., & Sahebkar, A. H. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.03.005 · Cited by 25
“Using Cas9 protein injection prevented any off-target effects (12).”
BackgroundTanhehco, Y. C., & Bhatia, M. (2019) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000541 · Cited by 24
“Finally, the CRISPR-Cas9 system for gene editing has recently been leveraged to upregulate the expression of HbF in patients with SCD after it was reported to have successfully corrected mutations in human embryos [34,35].”
BackgroundAmato, P., Daar, J., Francis, L., Klipstein, S., Ball, D., Rinaudo, P., Rajovic, A., Palmore, M., Tipton, S., Coutifaris, C., et al. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.10.012 · Cited by 28
“(81), in the second reported use of CRISPR/ Cas9 for embryo editing, used CRISPR/Cas9 to mutate CCR5 (gene responsible for HIV resistance in some individuals) in 3PN zygotes Again, low efficiency and off-target effects B Ma et al (17) (U.”
BackgroundMethodSelf-citationSaeed, K., Ayub, F., Durrani, M. A., & Mujahid, M. (2025) · The Microbe · doi:10.1016/j.microb.2025.100344 · Cited by 32
Application of CRISPR-Cas9 gene editing for congenital heart disease
Seok, H., Deng, R., Cowan, D. B., & Wang, D. (2021) · Korean Journal of Pediatrics · doi:10.3345/cep.2020.02096 · Cited by 23
Iltis, A. S., Hoover, S., & Matthews, K. R. W. (2021) · Frontiers in Political Science · doi:10.3389/fpos.2021.730869 · Cited by 31
In Vivo Genome Editing in Type I and II Methanotrophs Using a CRISPR/Cas9 System
Rumah, B. L., Stevens, B. H. C., Yeboah, J. E., Stead, C. E., Harding, E. L., Minton, N. P., & Zhang, Y. (2023) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00554 · Cited by 26
Neural/Bayes network predictor for inheritable cardiac disease pathogenicity and phenotype
Burghardt, T. P., & Ajtai, K. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.04.006 · Cited by 22
CRISPR‐Cas9: A cornerstone for the evolution of precision medicine
Razzouk, S. (2018) · Annals of Human Genetics · doi:10.1111/ahg.12271 · Cited by 25
Li, G., Liu, X., Huang, S., Zeng, Y., Yang, G., Lu, Z., Zhang, Y., Ma, X., Wang, L., Huang, X., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.05.021 · Cited by 23
Majzoub, A. A., Viana, M. C., Achermann, A. P. P., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164939 · Cited by 21
“Factors such as the sperm retrieval technique, histopathological patterns, hormone-based therapy prior to sperm retrieval, and varicocelectomy in selected cases, as well as the age of the female partner, influence ICSI outcomes in the NOA scenario.”
BackgroundHuman Embryo Editing: Opportunities and Importance of Transnational Cooperation
Pei, D., Beier, D. W., Levy‐Lahad, E., Marchant, G. E., Rossant, J., Belmonte, J. C. I., Lovell-Badge, R. H., Jaenisch, R., Charo, A., & Baltimore, D. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.09.010 · Cited by 22
“Recently, Ma and colleagues reported the correction of a four-base GAGT deletion in MYBPC3, one of the genes implicated in dominant hypertrophic cardiomyopathy, in pre-implantation human embryos (Ma et al., 2017).”
BackgroundSelf-citationStamatiadis, P., Boel, A., Cosemans, G., Popovic, M., Bekaert, B., Guggilla, R. R., Tang, M., Sutter, P. D., Nieuwerburgh, F. V., Menten, B., et al. (2021) · Human Reproduction · doi:10.1093/humrep/deab027 · Cited by 21
Kuno, A., Ikeda, Y., Ayabe, S., Kato, K., Sakamoto, K., Suzuki, S., Morimoto, K., Wakimoto, A., Mikami, N., Ishida, M., et al. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001507 · Cited by 20
CRISPR/Cas gene editing in the human germline
Bekaert, B., Boel, A., Cosemans, G., Witte, L. D., Menten, B., & Heindryckx, B. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.03.012 · Cited by 21
Reproductive options in mitochondrial disease
Smeets, H. J. M., Sallevelt, S. C. E. H., & Herbert, M. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-12-821751-1.00004-x · Cited by 28
CRISPR/Cas9 technology: applications in oocytes and early embryos
Zhang, Y., Yin, T., & Zhou, L. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04610-9 · Cited by 33
“With the advancement of microinjection technology, MYBPC3 mutation has been fixed through co-injection of sperm and CRISPR/Cas9 components into human metaphase II (MII) oocytes [35].”
BackgroundMethodIshino, T., Hashimoto, M., Amagasa, M., SAITO, N., Dochi, O., KIRISAWA, R., & Kitamura, H. (2018) · Biomedical Research · doi:10.2220/biomedres.39.95 · Cited by 23
Systems of Delivery of CRISPR/Cas9 Ribonucleoprotein Complexes for Genome Editing
Амирханов, Р. Н., & Stepanov, G. A. (2019) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162019060025 · Cited by 23
Saxena, S., & Kumar, S. (2020) · GeroScience · doi:10.1007/s11357-020-00167-3 · Cited by 24
Intergenerational monitoring in clinical trials of germline gene editing
Cwik, B. (2020) · Journal of Medical Ethics · doi:10.1136/medethics-2019-105620 · Cited by 20
Consumer Behavioral Intention of Adopting Emerging Healthcare Technology
Wei, X., Peng, X., & Prybutok, V. R. (2022) · IEEE Transactions on Engineering Management · doi:10.1109/tem.2022.3140952 · Cited by 22
“research directions and potential early applications of gene repair technology are to prevent inheritable disease among infants [4] because genetic conditions are a leading cause of birth defects”
BackgroundRNA therapeutics for heart disease
Majo, F. D., & Windt, L. J. D. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.037 · Cited by 21
Gene Editing in Clinical Practice: Where are We?
Mittal, R. D. (2019) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-018-0804-4 · Cited by 25
Applications of CRISPR systems in respiratory health: Entering a new ‘red pen’ era in genome editing
Moses, C., & Kaur, P. (2019) · Respirology · doi:10.1111/resp.13527 · Cited by 23
Test-tube embryos - mouse and human development in vitro to blastocyst stage and beyond
Govindasamy, N., Duethorn, B., Ozguldez, H. O., Kim, Y. S., & Bedzhov, I. (2019) · The International Journal of Developmental Biology · doi:10.1387/ijdb.180379ib · Cited by 20
The Wisdom of Germline Editing: An Ethical Analysis of the Use of CRISPR-Cas9 to Edit Human Embryos
Gumer, J. (2019) · The New Bioethics · doi:10.1080/20502877.2019.1606151 · Cited by 31
“Although the University of Oregon asserts that it largely avoided mosaicism in its germline editing experiment (Ma et al. 2017) – again, these results are being questioned (Egli et al. 2018) – any amount of mosaicism may prove dangerous.”
BackgroundGene Therapy in Cardiology: Is a Cure for Hypertrophic Cardiomyopathy on the Horizon?
Paratz, E. D., Mundisugih, J., Rowe, S. J., Kizana, E., & Semsarian, C. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.11.024 · Cited by 34
Computational approaches in design of nucleic acid-based therapeutics
Sherman, M. W., & Contreras, L. M. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.12.001 · Cited by 22
Blossom of CRISPR technologies and applications in disease treatment
Liu, H., Wang, L., & Luo, Y. (2018) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2018.10.003 · Cited by 21
“In human embryos, researchers corrected the heterozygous MYBPC3 mutation in human preimplantation embryos with precise CRISPR-Cas9 system and no off-target mutation was observed [147].”
BackgroundAn Intrapersonal Addition Paradox
Nebel, J. M. (2018) · Ethics · doi:10.1086/700085 · Cited by 27
TAF1-gene editing alters the morphology and function of the cerebellum and cerebral cortex
Janakiraman, U., Yu, J., Moutal, A., Chinnasamy, D., Boinon, L., Batchelor, S. N., Anandhan, A., Khanna, R., & Nelson, M. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104539 · Cited by 19
“Using this approach, we expect minimal to none offtarget activity of the Cas9 enzyme as we and others verified before (Moutal et al., 2017; Ma et al., 2017).”
Intergenerational Pathogen-Induced Diapause in Caenorhabditis elegans Is Modulated by mir-243
Gabaldón, C., Legüe, M., Palominos, M. F., Verdugo, L., Gutzwiller, F., & Calixto, A. (2020) · mBio · doi:10.1128/mbio.01950-20 · Cited by 29
“Likewise, mir-67 mutants exhibited reduced pathogen avoidance behavior, apparently due to a dysregulation in sax-7 targeting (44, 45).”
BackgroundTissue specificity of DNA repair: the CRISPR compass
da Silva, J. F., Meyenberg, M., & Loizou, J. I. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.07.010 · Cited by 18
The DNA-Dialogue: A Broad Societal Dialogue About Human Germline Genome Editing in the Netherlands
van Baalen, S., Gouman, J., Houtman, D., Vijlbrief, B., Riedijk, S. R., & Verhoef, P. (2021) · The CRISPR Journal · doi:10.1089/crispr.2021.0057 · Cited by 27
“4,5 8 Furthermore, it is widely recognized that HGGE raises diverse ethical and societal questions beyond its clinical safety and effectiveness.”
CRISPR-Cas9 Genome Engineering: Trends in Medicine and Health
Zaib, S., Khan, I. A., & Saleem, M. A. (2021) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557521666210913112030 · Cited by 22
Gupta, M., Gerard, M., Padmaja, S. S., & Sastry, R. K. (2020) · World Patent Information · doi:10.1016/j.wpi.2019.101944 · Cited by 24
Initial heritable genome editing: mapping a responsible pathway from basic research to the clinic
Ranisch, R., Trettenbach, K., & Arnason, G. (2023) · Medicine, Health Care and Philosophy · doi:10.1007/s11019-022-10115-x · Cited by 19
Arif, M., Nabavizadeh, P., Song, T., Desai, D. A., Singh, R. R., Bazrafshan, S., Kumar, M., Wang, Y., Gilbert, R., Dhandapany, P. S., et al. (2020) · Biophysical Reviews · doi:10.1007/s12551-020-00725-1 · Cited by 22
Gene Modulation with CRISPR-based Tools in Human iPSC-Cardiomyocytes
Han, J., & Entcheva, E. G. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10506-4 · Cited by 25
“Although CRISPR/Cas9 is an invaluable method for disease modelling, its potential use in vivo requires further exploration to overcome the limitations of the current delivery methods and the off-target events observed [45, 52, 60].”
BackgroundWhere Will We Draw the Line? Public Opinions of Human Gene Editing
Riggan, K. A., Sharp, R. R., & Allyse, M. A. (2019) · Qualitative Health Research · doi:10.1177/1049732319846867 · Cited by 22
Human Germline Genome Editing: An Assessment
Greely, H. T. (2019) · The CRISPR Journal · doi:10.1089/crispr.2019.0038 · Cited by 25
When is it Safe to Edit the Human Germline?
Baxter, J. K. (2021) · Science and Engineering Ethics · doi:10.1007/s11948-021-00320-x · Cited by 18
“Because of the unsafe nature of this technique, many scientists have called for a temporary ban on human GGE (Ibid, 2017; Baltimore et al., 2015; Ma et al., 2017).”
BackgroundGene Editing and Gene-Based Therapeutics for Cardiomyopathies
Ohiri, J. C., & McNally, E. M. (2018) · Heart Failure Clinics · doi:10.1016/j.hfc.2017.12.006 · Cited by 17
Development and Characterization of a Modular CRISPR and RNA Aptamer Mediated Base Editing System
Collantes, J. C., Tan, V. M., Xu, H., Ruiz-Urigüen, M., Alasadi, A., Guo, J., Tao, H., Su, C., Tyc, K. M., Selmi, T., et al. (2021) · The CRISPR Journal · doi:10.1089/crispr.2020.0035 · Cited by 18
Financial compensation of oocyte donors: an Ethics Committee opinion
(2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2021.03.040 · Cited by 17
Responsible governance of human germline genome editing in China
Peng, Y., Lv, J., Ding, L., Gong, X., & Zhou, Q. (2022) · Biology of Reproduction · doi:10.1093/biolre/ioac114 · Cited by 21
Advances in CRISPR/Cas gene therapy for inborn errors of immunity
Liu, X., Li, G., Liu, Y., Zhou, F., Huang, X., & Li, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1111777 · Cited by 28
“CRISPR/Cas HDR-mediated corrections of pathogenic mutations in pre-implantation human embryos have also been reported (187).”
BackgroundEthical issues in human germline gene editing: a perspective from China
Zhang, D., & Lie, R. K. (2018) · Bioethics News · doi:10.1007/s40592-018-0091-0 · Cited by 22
Edição genética: riscos e benefícios da modificação do DNA humano
Furtado, R. N. (2019) · Revista Bioética · doi:10.1590/1983-80422019272304 · Cited by 23
“2016 [acesso 2 set 2018];24(3):430-46.”
Bosshard, S., Duroy, P., & Mermod, N. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102691 · Cited by 16
Precision medicine for cardiovascular disease
Sedaghat‐Hamedani, F., Katus, H. A., & Meder, B. (2017) · Herz · doi:10.1007/s00059-017-4667-x · Cited by 18
“While some researchers already applied this technique to correct the genome in the case ofMYBPC3mutations in human embryos [31], our vision is rather to employ vectors for somatic gene repair in suitable high-risk patients.”
Efficient Zygotic Genome Editing via RAD51-Enhanced Interhomolog RepairPreprint
Wilde, J. J., Aida, T., Wienisch, M., Zhang, Q., Qi, P., & Feng, G. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/263699 · Cited by 17
Haploidy in somatic cells is induced by mature oocytes in mice
Lee, Y., Trout, A., Martí‐Gutiérrez, N., Kang, S., Xie, P., Mikhalchenko, A. E., Kim, B., Choi, J., So, S., Han, J., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03040-5 · Cited by 17
Self-citationPIWI-Interacting RNA (piRNA) and Epigenetic Editing in Environmental Health Sciences
Perera, B. P. U., Morgan, R. K., Polemi, K. M., Sala-Hamrick, K. E., Svoboda, L. K., & Dolinoy, D. C. (2022) · Current Environmental Health Reports · doi:10.1007/s40572-022-00372-6 · Cited by 19
Reproductive Embryo Editing: Attending to Justice
de Melo‐Martín, I. (2022) · The Hastings Center Report · doi:10.1002/hast.1406 · Cited by 17
“(Ma et al. 2017) Although reproductive genome editing is not yet an accepted clinical intervention, in November 2018, a researcher named He Jiankui announced that he had used it to create the first edited embryos to make them less susceptible for HIV infection.”
BackgroundHypertrophic Cardiomyopathy: Current Treatment and Future Options
Sebastian, S. A., Panthangi, V., Singh, K., Rayaroth, S., Gupta, A., Shantharam, D., Rasool, B. Q., Padda, I., Co, E. L., & Johal, G. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101552 · Cited by 16
Genomic Innovation in Early Life Cardiovascular Disease Prevention and Treatment
Li, C., Pan, Y., Zhang, R., Huang, Z., Li, D., Han, Y., Larkin, C. T., Rao, V., Sun, X., & Kelly, T. N. (2023) · Circulation Research · doi:10.1161/circresaha.123.321999 · Cited by 22
Next-generation CRISPR technology for genome, epigenome and mitochondrial editing
Lau, C., Liang, Q., & Zhu, H. (2024) · Transgenic Research · doi:10.1007/s11248-024-00404-x · Cited by 21
“There-after, several other studies have refined CRISPR tools to correct a pathogenic gene mutation in human pre-implantation embryos with negligible mosaicism and no off-target effects (Aschheim 2017; Ma et al. 2017).”
In Vitro Production of (Farm) Animal Embryos
Wrenzycki, C. (2018) · Springer eBooks · doi:10.1007/978-3-319-92327-7_12 · Cited by 19
Nestor, M. W., & Wilson, R. L. (2020) · Journal of Bioethical Inquiry · doi:10.1007/s11673-019-09957-7 · Cited by 19
Gene Editing and Alzheimer's Disease: Is There Light at the End of the Tunnel?
Stepanichev, M. Y. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.00004 · Cited by 18
“Thus, the question is what a period of ontogeny is suitable to correct the mutations? Although successful editing of a human embryo was reported three years ago (Ma et al., 2017) many ethical problems of this approach remain unresolved.”
BackgroundPatino, C. A., Mukherjee, P., Lemaitre, V., Pathak, N., & Espinosa, H. D. (2021) · SLAS TECHNOLOGY · doi:10.1177/2472630320982320 · Cited by 17
Gene Mutation Classification through Text Evidence Facilitating Cancer Tumour Detection
Gupta, M., Wu, H., Arora, S., Gupta, A., Chaudhary, G., & Hua, Q. (2021) · Journal of Healthcare Engineering · doi:10.1155/2021/8689873 · Cited by 16
“Later, in [31], Ma et al. described the correction strategy of heterozygous MYBPC3 (i.e., type of mutation) found in human preimplantation embryos with the specific CRISPR-Cas-stationed accuracy.”
BackgroundRetracteddel Pozo‐Rodríguez, A., Rodríguez‐Gascón, A., Rodríguez-Castejón, J., Vicente-Pascual, M., Gómez-Aguado, I., Battaglia, L., & Solinís, M. Á. (2019) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2019_109 · Cited by 28
CRISPR/Cas: History and Perspectives
Shmakova, A., Shmakova, O. P., Karpukhina, A. A., & Vassetzky, Y. S. (2022) · Russian Journal of Developmental Biology · doi:10.1134/s1062360422040075 · Cited by 21
“Введение в яйцеклетки компонентов CRISPR/Cas9 совместно со сперма-тозоидами (в рамках экстракорпорального опло-дотворения) предлагалось для повышения эф-фективности редактирования и снижения риска мозаицизма эмбрионов (Ma et al., 2017).”
BackgroundInfluentialCRISPR GENOME SURGERY IN THE RETINA IN LIGHT OF OFF-TARGETING
Cho, G. Y., Schaefer, K. A., Bassuk, A. G., Tsang, S. H., & Mahajan, V. B. (2018) · Retina · doi:10.1097/iae.0000000000002197 · Cited by 16
Advena-Regnery, B., Dederer, H., Enghofer, F., Cantz, T., & Heinemann, T. (2018) · Bioethics · doi:10.1111/bioe.12433 · Cited by 15
Dowaidar, M. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/3nwzd · Cited by 26
Erratic journey of CRISPR/Cas9 in oncology from bench-work to successful-clinical therapy
Sarkar, E., & Khan, A. A. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100289 · Cited by 19
Gantz, V. M., & Bier, E. (2022) · BioEssays · doi:10.1002/bies.202100279 · Cited by 17
Huang, C., Li, Q., & Li, J. (2022) · Medical Review · doi:10.1515/mr-2022-0029 · Cited by 20
“Interestingly, the mutation alleles were repaired using the maternal WT alleles instead of exogenous DNA templates, a process termed gene conversion [244, 254].”
BackgroundMethodStage-specific therapy for hypertrophic cardiomyopathy
Argirò, A., Zampieri, M., Marchi, A. G., Cappelli, F., Franco, A. D., Mazzoni, C., Cecchi, F., & Olivotto, I. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad042 · Cited by 17
“The technique proved to be accurate and a high number of wild-type homozygous embryos were created without off-target effects.(2) This technique will likely never enter clinical practice, as a pre-implant selection of mutationnegative embryos is obviously an easier alternative.”
MethodPapadopoulou, E., Bouzarelou, D., Tsaousis, G. S., Παπαθανασίου, Α., Vogiatzi, G., Vlachopoulos, C. V., Miliou, A., Papachristou, P., Prappa, E., Servos, G., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1202381 · Cited by 26
Tomita, A., Sasanuma, H., Owa, T., Nakazawa, Y., Shimada, M., Fukuoka, T., Ogi, T., & Nakada, S. (2023) · Nature Communications · doi:10.1038/s41467-023-41048-5 · Cited by 19
“Some have proposed that frequent IH-HR might enable germline gene therapies 48,49 , whereas others have demonstrated that CRISPR-mediated gene editing via DSBs can cause chromosomal disruption, such as large deletions or rearrangements 50 – 52 .”
The Dawn of In Vivo Gene Editing Era: A Revolution in the Making
Niazi, S. K. (2023) · Biologics · doi:10.3390/biologics3040014 · Cited by 23
Governing with public engagement: an anticipatory approach to human genome editing
Barlevy, D., Juengst, E. T., Kahn, J. P., Moreno, J. D., Lambert, L. M., Charo, A., Chneiweiss, H., Farooque, M., Guston, D. H., Hyun, I., et al. (2024) · Science and Public Policy · doi:10.1093/scipol/scae010 · Cited by 20
“…(CRISPR) due to its precision and ease of use (Gupta and Musunuru 2014); proof-of-principle for human embryo applications of genome editing (Liang et al. 2015; Kang et al. 2016; Ma et al. 2017); and the start of a first-in-human trial using CRISPR to treat sickle cell anemia (Gostimskaya 2022)).”
BackgroundMenezes, A. D. S., Silva, A. L. G. D. F. E., de Oliveira, H. L., de Lima, K. B. A., Porto, I. D. O. P., Pedroso, T. M. A., Silva, D. D. M. E., & Freitas, A. F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115855 · Cited by 15
“It is at the forefront of human germline therapy, with several studies reporting efficient and successful genetic editing in these embryos [44,46].”
BackgroundEstimating Demand for Germline Genome Editing: An In Vitro Fertilization Clinic Perspective
Viotti, M., Victor, A. R., Griffin, D. K., Groob, J. S., Brake, A. J., Zouves, C., & Barnes, F. L. (2019) · The CRISPR Journal · doi:10.1089/crispr.2019.0044 · Cited by 17
“4–10 Avoiding Inherited Genetic Disorders with Preimplantation Genetic Testing The field of IVF has made tremendous advances since its inception 40 years ago, perhaps none bigger than the introduction of preimplantation genetic testing (PGT, previously known as PGD/PGS).”
Janakiraman, U., Chinnasamy, D., Yu, J., Moutal, A., Boinon, L., Fukunaga, K., Khanna, R., & Nelson, M. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105006 · Cited by 16
“Using this approach, we expect minimal to none off-target activity of the Cas9 enzyme as we and others verified before (Moutal et al., 2017; Ma et al., 2017).”
Use of Customizable Nucleases for Gene Editing and Other Novel Applications
Reddy, P., Vilella, F., Belmonte, J. C. I., & Simón, C. (2020) · Genes · doi:10.3390/genes11090976 · Cited by 18
“Interestingly, during the correction of a pathogenic mutation in human embryos, DSBs have been repaired using endogenous HDR mechanism and wild-type allele as a template, which differs from the HDR efficiency observed in pluripotent stem cells [135].”
BackgroundSelf-citationGenome editing technologies: CRISPR, LEAPER, RESTORE, ARCUT, SATI, and RESCUE
Görücü Yılmaz, Ş. (2021) · IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund · doi:10.17179/excli2020-3070
Sharif, B., & Barua, M. (2018) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000408 · Cited by 18
‘Designer babies’ almost thirty years on
Handyside, A. H. (2018) · Reproduction · doi:10.1530/rep-18-0157 · Cited by 17
“2018) and in genome editing of human embryos (Ma et al. 2017).”
CRISPR in Sub-Saharan Africa: Applications and Education
Ogaugwu, C., Agbo, S. O., & Adekoya, M. A. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.07.012 · Cited by 16
“Proofs-of-principle in mice and preimplantation human embryos revealed the possibilities to correct b-thalassemia (related to SCA) and other pathogenic mutations using CRISPR-Cas9 alone or combined with other methods [7,8], supporting the view that CRISPR could become a method of choice for efficient and cost-effectiv…”
MethodCorrection of the pathogenic mutation in TGM1 gene by adenine base editing in mutant embryos
Dang, L., Zhou, X., Zhong, X., Yu, W., Huang, S., Liu, H., Chen, Y., Zhang, W., Yuan, L., Li, L., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.007 · Cited by 17
de Waal, E., Tran, T., Abbondanza, D., Dey, A., & Peterson, C. N. (2019) · Biochemistry and Molecular Biology Education · doi:10.1002/bmb.21280 · Cited by 14
State of Gene Therapy for Monogenic Cardiovascular Diseases
Bains, S., Giudicessi, J. R., Odening, K. E., & Ackerman, M. J. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.11.003 · Cited by 16
Tackling mosaicism in gene edited livestock
Salvesen, H. A., Grupen, C. G., & McFarlane, G. R. (2024) · Frontiers in Animal Science · doi:10.3389/fanim.2024.1368155 · Cited by 22
Counterpoint: The Potential Harms of Human Gene Editing Using CRISPR-Cas9
Baylis, F. E. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.278317 · Cited by 15
Rose, B. I., & Brown, S. (2019) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003327 · Cited by 17
de Wert, G. M. W. R., Heindryckx, B., Pennings, G., Clarke, A. J., Eichenlaub-Ritter, U., van El, C. G., Forzano, F., Goddijn, M., Howard, H. C., Radojkovic, D. P., et al. (2018) · Human Reproduction Open · doi:10.1093/hropen/hox024 · Cited by 19
“In a recent breakthrough article that appeared after the round of discussion in the professional Societies as discussed in the Introduction of this document, the group of Mitalipov (Ma et al., 2017) described the correction of a heterozygous mutation present in sperm by highly efficient genomic editing using CRISPR/Ca…”
BackgroundHypoplastic Left Heart Syndrome: Signaling & Molecular Perspectives, and the Road Ahead
Datta, S., Cao, W., Skillman, M., & Wu, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015249 · Cited by 19
Are we ready for genome editing in human embryos for clinical purposes?
Harper, J. C., & Schatten, G. P. (2019) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2019.103682 · Cited by 14
From laparotomy to laparoscopy to in vitro fertilization
Gomel, V. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.06.028 · Cited by 16
Metadata
- Authors
- Ma, H., Marti-Gutierrez, N., Park, S.-W., Wu, J., Lee, Y., Suzuki, K., Koski, A., Ji, D., Hayama, T., Ahmed, R., Darby, H., Van Dyken, C., Li, Y., Kang, E., Park, A.-R., Kim, D., Kim, S.-T., Gong, J., Gu, Y., Xu, X., Battaglia, D., Krieg, S. A., Lee, D. M., Wu, D. H., Wolf, D. P., Heitner, S. B., Belmonte, J. C. I., Amato, P., Kim, J.-S., Kaul, S., & Mitalipov, S.
- Affiliations
- Oregon Health & Science University (US)
- Institute for Basic Science (KR)
- Salk Institute for Biological Studies (US)
- Seoul National University (KR)
- BGI Group (China) (CN)
- Corresponding author
- Amato, Paula
- Kim, Jin-Soo
- Kaul, Sanjiv
- Mitalipov, Shoukhrat
- ORCID
- Venue
- Nature
- Published
- 2017-08
- Volume
- 548
- Issue
- 7668
- Pages
- 413-419
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2740810575
- Cited by
- 992
- References
- 48
- Citations by year
- 2026: 22 · 2025: 50 · 2024: 47 · 2023: 93 · 2022: 75 · 2021: 107 · 2020: 135 · 2019: 155 · 2018: 217 · 2017: 88
- Type
- journal article
- Language
- en
- Update notices
- expression_of_concern (2017-10-02)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Oregon Health and Science University
- Leona M. and Harry B. Helmsley Charitable Trust
- Consorzio Interuniversitario Biotecnologie
- Moxie Foundation
- Government of Jiangxi Province
- Institute for Basic Science (IBSR021-D1, R021-D1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Animal Genetics and Reproduction
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- germline editing, CRISPR/Cas9, MYBPC3 mutation, hypertrophic cardiomyopathy, preimplantation embryo, homology-directed repair, mosaicism, DNA double-strand break repair, cell cycle timing, preimplantation genetic diagnosis, off-target mutations
- MeSH terms
- Gene Editing, Myosin Binding Protein C, Adult, Alleles, Blastocyst, Carrier Proteins, Cell Division, Embryo, Mammalian, Genetic Complementation Test, Heterozygote, Homozygote, Humans, Male, Mosaicism, Mutation, Templates, Genetic, Zygote, S Phase, Gene Targeting, DNA Breaks, Double-Stranded, Recombinational DNA Repair, Clustered Regularly Interspaced Short Palindromic Repeats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.